Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02232516 · OUTCOME

Overall Survival (OS)

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma · Source last updated 2026-06-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
OS Probablilty
Interval / dispersion
95% Confidence Interval
Time frame
Reported at 1 and 2 years after the start of treatment

What was measured

Survival is defined as the duration of time from start of treatment to time of death, up to three years from the start of study treatment. Overall Survival (OS) is reported below as the proportion of patients who are alive at 1 and 2 years after starting treatment.

Groups in this outcome

Treatment (Romidepsin, Lenalidomide)

Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. romidepsin: Given IV lenalidomide: Given PO laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Romidepsin, Lenalidomide)23

Reported measurements

OS at year 1
Values in OS Probablilty · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Romidepsin, Lenalidomide)0.711Not reported0.5400.937Not reported
OS at year 2
Values in OS Probablilty · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Romidepsin, Lenalidomide)0.495Not reported0.3160.778Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.540
        upper Limit
        0.937
        value
        0.711
    title
    OS at year 1
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.316
        upper Limit
        0.778
        value
        0.495
    title
    OS at year 2
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    units
    Participants
description
Survival is defined as the duration of time from start of treatment to time of death, up to three years from the start of study treatment. Overall Survival (OS) is reported below as the proportion of patients who are alive at 1 and 2 years after starting treatment.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. romidepsin: Given IV lenalidomide: Given PO laboratory biomarker analysis: Correlative studies
    id
    OG000
    title
    Treatment (Romidepsin, Lenalidomide)
param Type
NUMBER
reporting Status
POSTED
time Frame
Reported at 1 and 2 years after the start of treatment
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
OS Probablilty

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice